SCHEMBL8534223

SCHEMBL8534223

COC1CCN(c2ccc(-c3csc(Nc4cc(S(N)(=O)=O)ccc4OC(C)C)n3)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.44
KMT2A Q03164 9/20 0.44
MAPT P10636 8/20 0.44
MAPK1 P28482 4/20 0.44
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 5/20 0.40
PIK3CA P42336 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37
TUBA1A Q71U36 1/20 0.37
TUBA1C Q9BQE3 1/20 0.37
TUBB6 Q9BUF5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8534195 0.92 MAPT (0.43) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8740282 0.92 MAPT (0.45) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL6128598 0.90 MAPT (0.42) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8740307 0.90 CA1 (0.46) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8534197 0.90 MAPT (0.41) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8740375 0.89 MAPT (0.42) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8533646 0.89 MAPT (0.45) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8521130 0.88 MAPT (0.44) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL8521083 0.88 MAPT (0.44) MEN1KMT2AMAPTMAPK1HTT
SCHEMBL6118003 0.88 MAPT (0.44) MEN1KMT2AMAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012068210-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, TIMP3 MEN1 2671/4885KMT2A 3083/4885MAPT 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.